AstraZeneca PLC Director/PDMR Shareholding (8429K)

TIDMAZN

RNS Number : 8429K

AstraZeneca PLC

26 September 2016

26 September 2016 16:00

Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

On 26 September 2016, the interest of Sean Bohen, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below.

The change in interest relates to the vesting of an award of AstraZeneca American Depositary Shares (ADSs) made in September 2015 under the AstraZeneca Restricted Share Plan.

One ordinary share equals two ADSs.

After sufficient vested shares were withheld to satisfy certain tax obligations arising on the vesting, Mr Bohen has become beneficially entitled to and has received 12,385 ADSs into a personal brokerage account.

For tax purposes, the fair market value of the shares at vest was $33.97 per ADS being the closing price on the last trading day preceding the vesting day.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  --------------------------------------------------------------- 
 a)   Name                       Sean Bohen 
---  -------------------------  ------------------------------------ 
 2    Reason for the notification 
---  --------------------------------------------------------------- 
 a)   Position/status            Executive Vice-President, 
                                  Global Medicines Development 
                                  and Chief Medical Officer 
---  -------------------------  ------------------------------------ 
 b)   Initial notification       Initial notification 
       /Amendment 
---  -------------------------  ------------------------------------ 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  --------------------------------------------------------------- 
 a)   Name                       AstraZeneca PLC 
---  -------------------------  ------------------------------------ 
 b)   LEI                        Not applicable 
---  -------------------------  ------------------------------------ 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  --------------------------------------------------------------- 
 a)   Description of             AstraZeneca PLC American 
       the financial              Depositary Shares 
       instrument, type 
       of instrument 
 
       Identification             CUSIP: 046353108 
       code 
---  -------------------------  ------------------------------------ 
 b)   Nature of the              Acquisition of AstraZeneca 
       transaction                American Depositary Shares 
                                  pursuant to the vesting of 
                                  an award under the AstraZeneca 
                                  Restricted Share Plan 
---  -------------------------  ------------------------------------ 
 c)   Price(s) and volume(s)       Price(s)   Volume(s) 
                                   ---------  ---------- 
                                    $33.97     12,385 
                                   ---------  ---------- 
---  -------------------------  ------------------------------------ 
 d)   Aggregated information     Not applicable - single transaction 
 
       - Aggregated volume 
 
       - Price 
---  -------------------------  ------------------------------------ 
 e)   Date of the transaction    26 September 2016 
---  -------------------------  ------------------------------------ 
 f)   Place of the transaction   New York 
---  -------------------------  ------------------------------------ 
 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

 
 Media Enquiries 
 Neil Burrows          UK/Global                   [phone] 
 Vanessa Rhodes        UK/Global                   [phone] 
 Karen Birmingham      UK/Global                   [phone] 
 Rob Skelding          UK/Global                   [phone] 
                                                   [phone] 
 Jacob Lund            Sweden                       20 
 Michele Meixell       US                          [phone] 
 Investor Relations 
 UK 
 Thomas Kudsk 
  Larsen                                           [phone] 
                       Finance, Fixed              [phone] 
 Craig Marks            Income, M&A                 764 
                       Respiratory & 
 Nick Stone             Autoimmunity               [phone] 
 Henry Wheeler         Oncology                    [phone] 
 Christer Gruvris      Infection & Neuroscience    [phone] 
 US 
                       Cardiovascular 
 Lindsey Trickett       & Metabolic Diseases       [phone] 
 Mitchell Chan          Oncology                   [phone] 
 Toll-free                                         [phone] 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUNUORNOAKUAR

(END) Dow Jones Newswires

September 26, 2016 11:00 ET (15:00 GMT)